Kafri Rachel, Langer Rami, Dvir Zeevi, Katz-Leurer Michal
Department of Physical Therapy, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Apr;18(4):407-11. doi: 10.1007/s00192-006-0163-1. Epub 2006 Jul 11.
The objective of this study was to compare the short-term effectiveness of rehabilitation treatment with a standard drug treatment for urge urinary incontinence (UUI). The study design includes parallel clinical trial in an outpatient urogynecologic clinic setting. The subjects were 44 women who suffered from UUI and who were systematically assigned to a rehabilitation group (REH) (N=24) or a medication group (MED) (N=20). The intervention for REH was consisted of five visits during a 3-month period of pelvic floor muscle training and behavioral training, whereas for MED was extended release oxybutynin at 5 mg/day, for 3 months. The urinary symptoms considered were frequency of voiding per day and night (freq/day and freq/night), number of incontinent episodes per week based on a bladder diary, and data based on the Incontinence Quality of Life Instrument (I-QoL). In the within-group comparison, both groups had improved significantly over time with respect to urinary symptoms and I-QoL (p<0.01). In addition, there was a significant group-time interaction effect on freq/day. While REH improved during the 3-month follow-up period, the MED group deteriorated to mean baseline value (p<0.01). A significant negative association was found between the urinary symptoms and the I-QoL at the end of follow-up (r (p)=-0.35 to -0.62, p<0.05). Three months after the intervention, both groups maintained the achievements of the intervention period. In addition, the REH group demonstrated additional improvement in mean freq/day while the condition of MED patients deteriorated to baseline values.
本研究的目的是比较康复治疗与标准药物治疗对急迫性尿失禁(UUI)的短期疗效。研究设计包括在门诊泌尿妇科诊所环境中进行的平行临床试验。受试者为44名患有UUI的女性,她们被系统地分配到康复组(REH)(N = 24)或药物治疗组(MED)(N = 20)。REH组的干预措施包括在3个月内进行5次盆底肌肉训练和行为训练,而MED组则服用5毫克/天的缓释奥昔布宁,持续3个月。所考虑的泌尿症状包括白天和夜间排尿频率(freq/day和freq/night)、基于膀胱日记的每周尿失禁发作次数以及基于尿失禁生活质量量表(I-QoL)的数据。在组内比较中,两组在泌尿症状和I-QoL方面均随时间有显著改善(p<0.01)。此外,在freq/day方面存在显著的组-时间交互效应。虽然REH组在3个月的随访期内有所改善,但MED组恶化至平均基线值(p<0.01)。随访结束时,发现泌尿症状与I-QoL之间存在显著的负相关(r(p)=-0.35至-0.62,p<0.05)。干预3个月后,两组均维持了干预期的成果。此外,REH组的平均freq/day有额外改善,而MED组患者的状况恶化至基线值。